Conference Abstracts | CrisPRO Research

CRISPRO · KNOWLEDGE BASE

Back to Research

AACR and conference abstracts — open slides on-site or the published citation.

Hygraph CMS

22352026
Intercepting metastasis: 8-step CRISPR design via multi-modal foundation models.
Intercepting metastasis: 8-step CRISPR design via multi-modal foundation models.\nAn eight-step CRISPR design workflow powered by multi-modal foundation models targets metastatic progression. The pipeline links genomic context, pathway priors, and guide RNA selection for interception of metastatic colonization.\nF Kiani\nCancer Research 86 (7_Supplement), 2235-2235, 2026\nPublished abstract: \nhttps://scholar.google.com/citations?view_op=view_citation&hl=en&user=HrO6JwkAAAAJ&citation_for_view=HrO6JwkAAAAJ:RYcK_YlVTxYC
Read more Published
B0652026
Abstract B065: Stage-aware CRISPR design for brain metastasis interception: Multi-modal validation of BBB extravasation and CNS colonization targets
Abstract B065: Stage-aware CRISPR design for brain metastasis interception: Multi-modal validation of BBB extravasation and CNS colonization targets\nStage-aware CRISPR designs prioritize blood–brain barrier extravasation and CNS colonization targets for brain metastasis. Multi-modal models validate target sets across metastatic stages before therapeutic design.\nF Kiani, SA Allah\nCancer Research 86 (6_Supplement), B065-B065, 2026\nPublished abstract: \nhttps://scholar.google.com/citations?view_op=view_citation&hl=en&user=HrO6JwkAAAAJ&citation_for_view=HrO6JwkAAAAJ:J_g5lzvAfSwC
Read more Published
LB-B0132026
Abstract LB-B013: Eight-Pathway transcriptomic biomarker outperforms PD-L1 for anti-PD-1 response prediction in melanoma
Abstract LB-B013: Eight-Pathway transcriptomic biomarker outperforms PD-L1 for anti-PD-1 response prediction in melanoma\nAn eight-pathway transcriptomic signature predicts anti-PD-1 response in melanoma more accurately than PD-L1 alone. The biomarker integrates immune and tumor-intrinsic programs for responder stratification.\nF Kiani, SA Allah\nCancer Immunology Research 14 (2_Supplement), LB-B013-LB-B013, 2026\nPublished abstract: \nhttps://scholar.google.com/citations?view_op=view_citation&hl=en&user=HrO6JwkAAAAJ&citation_for_view=HrO6JwkAAAAJ:NaGl4SEjCO4C
Read more Published
B0252025Slides
Abstract B025: An agentic platform for designing cancer immunotherapies: From automated variant interpretation to in silico therapeutic validation
Abstract B025: An agentic platform for designing cancer immunotherapies: From automated variant interpretation to in silico therapeutic validation\nCrisPRO presents an agentic workflow that connects variant interpretation, therapeutic hypothesis generation, and in silico validation for cancer immunotherapy design. The platform automates evidence synthesis across genomic and pathway layers.\nF Kiani, R Nayeem\nCancer Immunology Research 13 (9_Supplement), B025-B025, 2025\nPublished abstract: \nhttps://aacrjournals.org/cancerimmunolres/article/13/9_Supplement/B025/765414/Abstract-B025-An-agentic-platform-for-designing
View slides Published